BNTX Latest Headlines

BioNTech raises 2026 revenue guidance midpoint as pumitamig combination strategy moves into a first global Phase 3 ADC trial

Market Chameleon (Tue, 3-Nov 7:11 AM)

Most and least shorted mid- to mega-cap healthcare stocks at the end of October

at seekingalpha.com (Tue, 3-Nov 10:00 AM)

BioNTech Reports Third-Quarter Results, Advances Oncology Pipeline

at www.tipranks.com (Tue, 3-Nov 9:00 AM)

BioNTech Reports Third-Quarter and Nine-Month 2026 Results

at www.tipranks.com (Tue, 3-Nov 8:59 AM)

Pfizer hikes 2026 outlook despite flat Q3 revenue: names new CFO

at seekingalpha.com (Tue, 3-Nov 7:24 AM)

BioNTech beats top-line and bottom-line estimates; raises FY26 outlook

at seekingalpha.com (Tue, 3-Nov 6:51 AM)

Here are the major earnings before the open Tuesday

at seekingalpha.com (Mon, 2-Nov 6:00 PM)

Analysts Offer Insights on Healthcare Companies: BrightSpring Health Services, Inc. (BTSG), Biogen (BIIB) and BioNTech SE (BNTX)

at www.tipranks.com (Mon, 2-Nov 11:26 AM)

BioNTech Q3 2026 Earnings Preview

at seekingalpha.com (Mon, 2-Nov 10:20 AM)

BioNTech’s DYNASTY-Breast02 Phase 3 readout hits PFS endpoint, but companies flag “limited” benefit and higher ILD rates

Market Chameleon (Mon, 26-Oct 7:07 AM)

BioNTech says BNT113 missed progression-free survival bar, but AHEAD-MERIT continues with overall survival as the potential win condition

Market Chameleon (Tue, 13-Oct 11:14 AM)

BioNTech’s BNT113 trial misses PFS goal, but overall survival readout can still define success

Market Chameleon (Tue, 13-Oct 7:12 AM)

BioNTech Unveils First Global Data for Novel Lung Cancer Combination at WCLC 2026—What Does This Mean for Its Pipeline?

Market Chameleon (Fri, 21-Aug 11:08 AM)

BioNTech Showcases Pioneering Lung Cancer Pipeline and Unveils First-Ever Data for Novel Combination Therapy at WCLC 2026

Market Chameleon (Thu, 20-Aug 7:10 AM)

BioNTech Appoints Guido Oelkers as CEO: Strategic Shift Aims for Multi-Product Success by 2030

Market Chameleon (Mon, 3-Aug 8:40 AM)